Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

632
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
632
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

595
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
595
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

464
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
464
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

495
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
495
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

612
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
612
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

518
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
518

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyperoxia reflects poor native cardiac function and demonstrates cardiac index-dependent associations with mortality in VA-ECMO patients.

European heart journal. Acute cardiovascular care·2026
Same author

Reply: CICU Workforce Survey: Interpret With Caution.

JACC. Advances·2026
Same author

Leadless Pacemaker Dysfunction From Interference by a Retained Transvenous Pacemaker With Active Minute Ventilation Sensor.

JACC. Case reports·2026
Same author

Cardiac Intensive Care Unit Appropriate Patient Selection and Triage: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Streamlining the workflow: evaluation of ECG-gated computed tomography as a comprehensive imaging modality prior to intervention for mitral valve regurgitation.

Journal of cardiothoracic surgery·2026
Same author

Variation in Vasoactive Treatment Selection for Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network (CCCTN).

Circulation. Heart failure·2026

Related Experiment Video

Updated: Jan 28, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

765

Pulmonary Hypertension in HIV.

Binaya Basyal1, Harish Jarrett2, Christopher F Barnett2

  • 1MedStar Heart and Vascular Institute, Washington Hospital Center, Washington, DC, USA.

The Canadian Journal of Cardiology
|March 4, 2019
PubMed
Summary

Human immunodeficiency virus-associated pulmonary arterial hypertension (HIV-PAH) requires prompt recognition due to severe health impacts. Early diagnosis and targeted therapies are crucial for improving outcomes in this chronic complication.

More Related Videos

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

911
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.7K

Related Experiment Videos

Last Updated: Jan 28, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

765
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

911
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.7K

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pulmonology

Background:

  • Human immunodeficiency virus-associated pulmonary arterial hypertension (HIV-PAH) presents significant morbidity and mortality.
  • Antiretroviral therapy has shifted focus towards managing chronic cardiopulmonary issues in HIV patients.
  • Nonspecific symptoms necessitate a high index of clinical suspicion for timely HIV-PAH diagnosis.

Purpose of the Study:

  • To highlight the importance of recognizing HIV-PAH.
  • To underscore the diagnostic challenges and current understanding of its pathogenesis.
  • To emphasize the need for further research into mechanisms, diagnostics, and therapeutics.

Main Methods:

  • Review of current literature on HIV-PAH.
  • Analysis of clinical presentation and diagnostic considerations.
  • Discussion of implicated viral factors and pathogenic pathways.

Main Results:

  • HIV-PAH is a serious complication requiring clinical vigilance.
  • Diagnostic delays are common due to nonspecific symptoms.
  • The precise pathogenic mechanisms involving viral proteins remain unclear.

Conclusions:

  • Effective management of HIV-PAH necessitates early detection.
  • Further research is essential to understand HIV-PAH pathogenesis.
  • Novel diagnostic tools and therapeutic targets are needed to improve patient prognosis.